5 years' experience of 5-S-cysteinyldopa in melanoma diagnosis.
Determinations of the urinary excretion of 5-S-cysteinyldopa were performed in 571 patients previously treated by surgery for melanoma or melanoma metastasis. 90% of the 161 patients with metastases showed values exceeding 0.15 mg/24 h, and 9% of the 410 patients without metastases had such values. The increase in 5-S-cysteinyldopa excretion was generally more pronounced in men with metastases than in women, 98% of the men and 77% of the women with metastases showing values exceeding 0.15 mg/24 h. High levels of 5-S-cysteinyldopa are of grave prognostic significan4% died within one month, and only 3% survived for more than a year. In Sweden, determination of 5-S-cysteinyldopa in patients operated on for melanoma gives maximum information in the winter (October--March), when sun exposure does not influence the excretion levels.
D000328:Adult; D000368:Aged; D003548:Cysteinyldopa / Q000378:metabolism / Q000652:urine*; D004295:Dihydroxyphenylalanine / Q000031:analogs & derivatives*; D005260:Female; D006200:Hair Color; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000175:diagnosis / Q000652:urine*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012737:Sex Factors; D012878:Skin Neoplasms / Q000175:diagnosis / Q000652:urine*; D013472:Sunlight
D003548:Cysteinyldopa; D004295:Dihydroxyphenylalanine